# BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

> **NCT06787989** · PHASE1 · RECRUITING · sponsor: **iCell Gene Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Refractory Immune Cytopenia

## Interventions

- **BIOLOGICAL:** BCMA-CD19 cCAR T cells

## Key facts

- **NCT ID:** NCT06787989
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-31
- **Primary completion:** 2026-08
- **Final completion:** 2027-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787989, "BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06787989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*